Halozyme Therapeutics (HALO) Capital Expenditures (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Capital Expenditures data on file, last reported at $3.7 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $3.7 million, up 666.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (down 57.03% YoY), and the FY2025 annual result was $902000.0, down 91.57% from the prior year.
• Capital Expenditures advanced to $3.7 million in Q1 2026 per HALO's latest filing, from -$4.6 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $14.8 million in Q4 2023 and troughed at -$10.7 million in Q2 2023.
• A 5-year average of $2.1 million and a median of $1.5 million in 2024 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 2221.84% in 2023 and fell as far as 1207.64% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $2.3 million in 2022, then jumped by 529.74% to $14.8 million in 2023, then sank by 79.32% to $3.1 million in 2024, then tumbled by 252.06% to -$4.6 million in 2025, then soared by 180.61% to $3.7 million in 2026.
• Business Quant data shows HALO's Capital Expenditures at $3.7 million in Q1 2026, -$4.6 million in Q4 2025, and $3.0 million in Q3 2025.